

Q2 2023





Forward-Looking Statements

This presentation contains forward-looking statements. All statements other than statements of historical facts may be forward-looking statements. Forward-looking statements generally relate to future events and include, without limitation, projections, forecasts and estimates about possible or assumed future results of our business, financial condition, liquidity, results of operations, plans, and objectives. Some of these statements may include words such as "expects," "anticipates," "believes," "estimates," "targets," "plans," "potential," "intends," "projects," and "indicates."

Although they reflect our current, good faith expectations, these forward-looking statements are not a guarantee of future performance, and involve a number of risks, uncertainties, estimates, and assumptions, which are difficult to predict. Some of the factors that may cause actual outcomes and results to differ materially from those expressed in, or implied by, the forward-looking statements include, but are not necessarily limited to: the current noncompliance with the minimum bid requirement pursuant to the Nasdaq Listing Rules; our ability to consummate our convertible note exchange and secure additional financing, the duration and magnitude of the COVID-19 pandemic and related containment measures; our management of growth; the execution of our business strategies, implementation of new initiatives, and improved efficiency; our sales and marketing efforts; our manufacturing capacity, performance, and cost; our ability to obtain future regulatory approvals; our financial estimates and needs for additional financing; consumer acceptance of and competition for our clear aligners; our relationships with retail partners and insurance carriers; our R&D, commercialization, and other activities and expenditures; the methodologies, models, assumptions, and estimates we use to prepare our financial statements, make business decisions, and manage risks; laws and regulations governing remote healthcare and the practice of dentistry; our relationships with vendors; the security of our operating systems and infrastructure; our risk management framework; our cash and capital needs; our intellectual property position; our exposure to claims and legal proceedings; and other factors described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2022 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.

New risks and uncertainties arise over time, and it is not possible for us to predict all such factors or how they may affect us. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We are under no duty to update any of these forward-looking statements after the date of this presentation to conform these statements to actual results or revised expectations. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation.

Market and Industry Data

This presentation also contains estimates and other statistical data obtained from independent parties and by us relating to market size and growth and other data about our industry and ultimate consumers. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. In addition, projections, assumptions, and estimates of our future performance and the future performance of the geographic and other markets in which we operate are necessarily subject to a high degree of uncertainty and risk. We provide additional disclosures regarding our marketing claims on our web site which can found at smiledirectclub.com/claims/.

Non-GAAP Financial Measures

This presentation contains certain non-GAAP financial measures, including adjusted EBITDA ("Adjusted EBITDA") and Free Cash Flow. We utilize certain non-GAAP measures, including Adjusted EBITDA, and Free Cash Flow to evaluate our actual operating performance and for planning and forecasting of future periods. These non-GAAP measures should not be considered in isolation or as a substitute for the related GAAP measures, and other companies may define such measures differently. We provide a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures in the appendix to this presentation and in our Current Report on Form 8-K announcing our quarterly earnings results, which can be found on the SEC's website at www.sec.gov and our website at investors.smiledirectclub.com. We do not provide a reconciliation of forward-looking Adjusted EBITDA to the most directly comparable GAAP financial measure (net loss), as the reconciliation to the corresponding GAAP measure is not available due to the variability, complexity and limited visibility of the non-cash items that are excluded from forward-looking Adjusted EBITDA.

This presentation is a supplement to, and should be read in conjunction with, SmileDirectClub's earnings release for the quarter ended June 30, 2023.



Our vision.

We started by disrupting the 120+ year old orthodontic industry.

We created the first telehealth platform for orthodontia that connects doctors with their patients, removing significant barriers to open teeth straightening to entirely new populations where it was historically out of reach. Now, with a winning team and bestin-class partnerships, we're making it increasingly convenient, more affordable, and more comfortable by utilizing the transformative innovations in digital scanning, materials science, and taking a "big data" approach to treatment planning and in-treatment monitoring to improve outcomes.



Evolve the brand into an everyday oral care staple: Through transformative innovation, we will

democratize access to quality daily routine oral care products with superior performance. SmileDirectClub should own the oral care half of the bathroom vanity countertop. This grows our brand presence and connection points by offering oral care products in retail, and online, and through subscription models, keeping us physically present to be top of mind.



Extend the access spectrum: Building on the success we've seen with our telehealth model, we will launch offerings that appeal

to even more people,


including orthodontia's traditional customers. This includes a hybrid (in-person and virtual) service model for teens and high-income households delivered via a large and comprehensive network of dental offices.




Establish SDC as the largest referrer of dental care: Strengthen our Partner

Network by introducing partner practices to new patients as the first step in their teeth straightening journey and through Al-assisted diagnosis via connected devices.

History of Disrupting the Aligner Market



Culture of Continual Innovation, Improvement and Evolution in How We Serve Our Customers




smile

1) Source: CarePlus Quant Research, April 2022, n = 2,126 (US HHI \$125K+). Research with US gen pop, 18-65 years old, who are interested in straightening their teeth, or their teen's, in next 3 years, or have straightened their teeth or their teen's in the past 3 years, or are currently in treatment for themselves or their teen's.

Our strategic pillars.

Our Mission: Democratize access to a smile each and every person loves.



Key initiative overview.






SDC Has Reimagined the Way It Wins Customers

Meeting the changing needs of consumers via two key strategic growth initiatives

	Description	Status
<image/> <section-header></section-header>	 Al-powered mobile 3D scanning technology Enables acceleration of draft treatment plan from weeks to minutes, driving improved sales conversion Platform encourages referrals (sharing) 	Q4 2022 Australia launch Q2 2023 U.S. pilot launch
T	 Opportunity to upsell CarePlus through all U.S. SmileShops Utilizes Partner Network of dentists and orthodontists to provide hybrid in-person and virtual care 	Pilot launched in 4 U.S. markets (14 locations);
CarePlus Premium Hybrid Offering	 Enhanced care at higher price point but similar marketing expense as Care, resulting in higher EBITDA margins 73% of higher household income customers indicated interest to purchase¹ 	Q3 2023 U.S. nationwide launch to all SmileShops

Our SmileMaker Platform uses Al scanning through your smartphone to deliver a view of your potential new smile in minutes.


This transformative process shrinks the ability to scan and buy your aligners from weeks to minutes.



Entire scan done in approximately 2 minutes



SmileMaker Reduces Friction by Shortening the Customer Acquisition Funnel



Partner network provides CarePlus access to target customer.





smile

Journey entry points primarily via SmileMaker or SmileShop scans and secondarily via the Partner Network



Mandatory in person office visit required via Partner Network or SmileShop

11

CarePlus research confirms strength of offering.

HHI Consumers

CarePlus is a compelling proposition for HHI consumers. 73% of higher household income customers surveyed indicated a likelihood to purchase.¹

Interest in CarePlus concept by income bracket

	CarePlus \$3900
Overall (incomes \$25K and up)	70%
Under \$125K (net)	68%
\$25,000 to \$49,999	61%
\$50,000 - \$74,999	66%
\$75,000 - \$124,999	75%
\$125K+ (net)	73%
	72%
\$150,000 to \$199,999	71%
\$200,000 to \$299,999	73%
\$300,000 or more	83%


Current Partners

Interest in CarePlus is strong with existing Partner Network partners to expand their offering with CarePlus.²

92%

of current partners would like to have both traditional SmileDirectClub & SmileDirectClub CarePlus options

Because SmileDirectClub CarePlus...





1) Source: CarePlus Quant Research, April 2022, n = 2,126 (US HHI \$125K+). Research with US gen pop, 18-65 years old, who are interested in straightening their teeth, or their teen's, in next 3 years, or have straightened their teeth or their teen's in the past 3 years, or are currently in treatment for themselves or their teen's. 2) Source: Qualitative Research conducted by a third-party, Actionable research, May-June 2022, n = 12. Research with Partner Network dentists with practices that serve mostly higher income households (\$125K+).

CarePlus and Care meet unique customer preferences.

Which works best for you?	Care Plus+ \$115/month for 35 months with \$500 down."	Care \$89/month
Choice of payment options	Or a one-time payment of \$3900.	Or a one-time payment of \$2250.
Choice of Fulltime or Nighttime Aligners™	~	\checkmark
Lifetime Smile Guarantee'''	~	\checkmark
Doctor-directed care	~	\checkmark
Regular Smile Check-ins"	~	\checkmark
Personal oversight by a CarePlus dental team	~	
In-person check-ins available with a local partner dentist	~	
2-year supply of retainers included	~	
Custom contoured aligners with scalloped edges	~	
Oral care accessories included	 Image: A second s	
Aligner delivery	1 week	3-4 weeks



 SmilePay[™] is \$115/month for 36 months at 13.269% APR with \$500 deposit (\$4640 total) for CarePlus. SmilePay[™] is \$89/month for 28 months with \$250 deposit (\$2742 total) for Care. APR varies. See SmileDirectClub.com/pricing/apr-Financing for financing details for your state.

2) Terms and conditions apply. See SmileDirectClub.com/guarantee for details.

Multiple avenues to achieve outsized growth.

Channel / Product

smile

Organic Volume Growth and Footprint Expansion



- ✓ Grow through organic customer penetration with normalizing economic backdrop
- ✓ Continue to focus marketing efforts to enhance brand awareness and adoption
- Strategic and disciplined expansion in targeted markets and within dental offices

Retail Partnerships and Adjacent Product Expansion



- ✓ Expand LTV through additional oral care and ancillary products
 - ✓ Retainers
 - ✓ Whitening treatments
 ✓ Oral care products
- Expand key retail partnership with Walmart and others, that serves as potential on-ramps to expand brand awareness

SmileMaker makes it easier to get started





- ✓ Leverage our growing innovation portfolio to launch new products, features and services
- ✓ Reduces timeline for customers to make purchasing decision from days or weeks to minutes
- ✓ Increase sales conversion and customer access to drive revenue growth

Successfully Target Higher Income Consumers



- ✓ Sell to higher income customers and teens
- ✓ Grow our professional channel – the Partner Network using CarePlus
- ✓ Move upstream by adding premium features, services, and experience through CarePlus
- ✓ Upsell CarePlus through our dual journey offering at SmileShops

A brand customers love & a business positioned for growth.





Brand and business model are well positioned to take advantage of large market with unique set of strategic assets.

1	Large and growing market	 Global orthodontics market is large and underserved, and TAM is expanding as aligners are more accessible Secular shift from wires and brackets to clear aligners COVID-19 has accelerated facetime: we've never been more aware of our own smiles
2	Trusted brand among customers & professionals	 Brand that consumers love (more than 2.0M smiles straightened) Second largest aligner brand and largest telehealth orthodontics brand in the world Premier teledentistry platform offering consumers accessibility & convenience
3	Leading orthodontic telehealth channel	 Largest telehealth orthodontic channel in the world provides attractive unit economics and substantial growth despite temporary macroeconomic factors Strong omnichannel presence maximizes consumer addressability Closed loop system offers optimal conversion from sophisticated CRM strategy and opportunities to enhance clinical outcomes from robust data library
4	Differentiated value proposition via teledentistry platform	 Complementary to telehealth offering, meeting patients where and when they are: in-chair or at home Professional channel strategy enhances options for consumers to seek treatment, broadening addressability Addresses key consumer demands offering convenience, access and lower cost of care
5	Vertically integrated model	 Substantial investment in treatment planning, manufacturing, contact center and teledentistry platform >\$400M of capex, including streamlined state-of-the-art manufacturing facility in Tennessee Vertically integrated model allows business to gain profitable leverage on scale and effectively focus on the end-to-end customer experience
smil	e »*	16

We've brought >2.0MM smiles to customers worldwide through our professional network of licensed orthodontists & dentists.



2.0M+ smiles straightened



232K initial aligner orders shipped¹




10M+ annual aligners trays produced²



An affiliated network of state-licensed doctors in our telehealth platform



\$6B+ saved by consumers who chose SmileDirectClub aligners over braces since 2014³




smile

1) Shipped in 2022. 2) Produced in 2022. 3) Calculated using the SinglePay price for SmileDirectClub aligners as of 4/20/2022 vs. average fees (including diagnostics and inperson exams) for treatment of mild-to-moderate malocclusion with braces as reported in a survey of orthodontists. Price comparison does not include additional costs, such as retainers. As treatment is highly individualized, results may not be the same.

We have built a brand that our customers love.

We have made considerable progress on brand perception, and our satisfaction scores consistently track higher than telehealth peers.



Total Google/Trustpilot Reviews

smile OFRECT CLUP

Source: Internal company surveys, public information. Data as of May 2023 ¹Average of Google and Trustpilot Review Ratings. ²Source: Third-party NPS scores were independently sourced and calculated surveying 748 customers who completed clear aligner therapy with SDC, Invisalign, or teledentistry competitors in the last 12 months.

...and we continue to make progress in building credibility with the dental community.

We have a huge growth opportunity with GPs and the Partner Network, especially with the CarePlus offering. Doctors have high awareness of SmileDirectClub, are open to our offering, and are compelled by our value proposition.

200K General Practices (GPs) in North America looking to grow their patient base and revenue	75% People worldwide eligible for treatment – a missed opportunity for GPs	85% SDC's awareness with GPs is second only to Invisalign (95%) ¹
2% Total GP revenue that is orthodontics	61% Doctors who have some degree of interest in being part of our Partner Network and offering	Grow revenue The reason GPs are most interested in joining the Partner Network ¹

Our industry memberships, affiliations and partnerships are growing, most recently with the American Academy of Clear Aligners (AACA), which has turned from actively campaigning against SDC to asking us to become a member as demonstrated by their recent retraction in the AACA Journal Fall 2021 Issue.²


SmileDirectClub to patients¹





Customers continue to choose SDC – now with even more options.

Orthodontists have traditionally purchased invisible aligners from a wholesaler or manufacturer, marked up the cost and then sold them to consumers for \$5,000-\$8,000. SDC's proprietary telehealth platform offers consumers the ability to get the same clinically safe and effective treatment, but without the markup.



4 Differentiated value proposition via teledentistry platform

Utilizing teledentistry to offer clear aligners affordably and conveniently.

Traditional orthodontic model

smile

\$2,250⁽¹⁾

Cost

\$5,000 - \$8,000



Convenience

- 10 15 orthodontist visits
- 12 24 months



Access

Limited access to treatment (Only approximately 40% of U.S. counties have orthodontists)

Financing

Barred by poor credit



Doctor-directed remote teledentistry In-office visit optional

5 – 10 months

Kits, SmileShops, dentist office

Access across U.S., Canada, U.K., Australia and Ireland


Captive financing for accessible credit

100% approval rating

smile

(1) Increased to \$2,250 from \$2,050 in July 2023 for U.S.

Substantial strategic value in vertically integrated business model.



Facilities Overview

Antioch & Columbia, TN

Alajuela, Costa Rica



307K sq. ft combined



- 45K sq. ft.

Commentary

- Vertically integrated business model allows the company to gain profitable leverage on scale and provide customers the best experience possible
- Nashville, TN state-of-the-art facility represents America's largest 3D printing and clear aligner production facility
- >\$400M capex over last 5 years resulted in streamlined manufacturing, positive trends and better customer experience
 - Faster turnaround times
 - Greater productivity and reduced labor
 - Reduction in scrap _
 - Higher quality aligner trays
- Investment in proprietary treatment planning software and virtual tools drive greater automation, improved outcomes and better customer experience
- 2nd gen machines producing ~95% of aligners
- Full redundancy back up facility in Columbia, TN



Produced 10M+ individual aligner trays in 2022, averaging over 28K per day



Q2 financial results.





Q2 2023 results.

- Revenue for the quarter was \$101.8 million, which is down (19.1%) year-over-year due to macroeconomic conditions and down (15.0%) from Q1 2023, following typical seasonal trends of sequential decline.
- Gross margin for the quarter was 71.6%, which represents a (129 bps) decrease year-over-year, driven by the deleveraging of fixed expenses on lower aligner volumes.
- Q2 Adjusted EBITDA⁽¹⁾ improvement of \$12.9 million over the first quarter of 2023, and an improvement of \$9.6 million over the prior year period at (\$13.6) million, driven primarily by cost control actions and increased marketing efficiencies despite a (\$24.0mm) decrease in year-over-year revenue.
- Net loss for the quarter was (\$53.8mm), an \$11.7mm year-over-year improvement over Q2 2022.
- Q2 Free Cash Flow improved \$7.5 million yearover-year compared to Q2 2022 and improved \$12.5 million sequentially compared to Q1 2022. On a YTD basis, Free Cash Flow improved by over \$43.0 million compared to the prior year.

	Q2 2023		ြ ၀ပြ		ΥοΥ
Net Revenue	\$	101.8mm	(15.0%)		(19.1%)
Gross Profit	\$	\$ 72.9mm			(20.5%)
Gross Margin %		71.6%	(91 bps)	(129 bp:	
Adjusted EBITDA ⁽¹⁾	\$	(13.6mm)	\$ 12.9mm	\$	9.6mm
EPS, Diluted	\$	(0.13)	\$ 0.03	\$	0.04
Free Cash Flow ⁽¹⁾	\$	(28.1mm)	\$ 12.5mm	\$	7.5mm

Year-Over-Year Financial Results (\$ in millions)




Q2 2023 revenue decreased \$24 million compared to Q2 2022 while Adjusted EBITDA increased \$10 million and Free Cash Flow improved \$8 million

smile

Gross margin.

- Gross margin for the quarter was 71.6%, which represents a (91 bps) decrease from prior year and a (129 bps) decrease compared to Q1 2023.
 - Lower gross margin rate was driven by the deleveraging of fixed expenses on lower aligner volumes.
- We continue to leverage our manufacturing automation enhancements with our 2nd Gen machines producing over 95% of our aligners in the quarter.
- The Q2 2023 decline in gross margin dollars compared to prior year was driven by lower aligner shipments as a result of the challenging macroeconomic environment.
 - Sequential first quarter to second quarter gross profit dollar decline follows historical seasonal trends



smile

(1) In Q4 2021, one-time costs related to the implementation of our internal treatment planning software, SmileOS and lower retail margin, primarily 25 due to higher expansion costs and excess inventory costs had an approximate 400 bps impact on margin.


Marketing & selling.

- Marketing and selling expenses were \$50 million, or 48.8% of net revenue in the quarter compared to 56.6% of net revenue in Q2 2022.
 - Total spend was down \$22mm as we continue to focus on marketing efficiency and rationalized store costs.
- Regarding locations, we had 128 permanent SmileShop locations as of quarter end, compared to 108 locations at the end of Q1 2023.
- We also held 58 pop-up events over the course of the quarter, for a total of 186 location sites at the end of the quarter.
- Current Partner Network global locations are now 1,156 active or pending training
 - Partner Network growth driven by new CarePlus rollout in 2023

Referrals as a % of Aligner Orders

Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022		Q4 2022		Q2 2023
21%	21%	20%	20%	20%	21%	21%	20%	19%	20%


Marketing & selling expenses (\$ in millions)





General & administrative.

- General and administrative expenses were \$60mm in Q2, compared to \$72 million in Q2 2022 and \$65mm in Q1 2023.
 - Declines due to cost reduction initiatives since Q1 2022
- Cost actions taken in January 2023 achieved full run rate savings in Q2 2023
- We plan to stay vigilant with cost control throughout 2023 and beyond, as we focus on continuing to leverage this line item.







Other expenses, Adj. EBITDA, and Net income.

- Interest Expense:
 - Totaled \$8.5 million in Q2 2023, of which \$7.1 million is associated with the debt facility secured in April 2022 and \$1.4 million was deferred loan costs from our convertible bonds and capital lease expense
- Other:
 - Other store closure and restructuring costs were ~\$8.5 million primarily related to severance costs, lease and international exit costs.
 - Unrealized currency loss impact of \$0.3 million.
- Q2 Adjusted EBITDA⁽¹⁾ was (\$13.6) million for the quarter, an improvement of \$13mm from Q1 2023 and \$10mm from Q2 2022.
 - US/Canada Adjusted EBITDA was (\$5.8) million
 - Rest of World Adjusted EBITDA was (\$7.8) million

Net income (Loss) (\$ in millions)



Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023



smile

Balance sheet highlights.

- We ended Q2 with \$58.0 million in cash and cash equivalents.
- Cash from operations for the second quarter was (\$17.8) million which is consistent with Q2 2022.
- Cash spent on investing for the second quarter was (\$10.2) million, down \$7.6mm from Q2 2022.
- Free Cash Flow was (\$28.1) million in the quarter, an improvement of \$7.5mm compared to (\$35.6) million in Q2 2022.
- In Q2 2023, SmilePay financing usage, as a percentage of total aligners purchased was 66.4%, which increased about 500 bps compared to Q1 2023.
- Overall, SmilePay delinquency rates continue to be in line with past performance.
- In August, our founders provided a \$10.0 million revolving line of credit to fund working capital and the new initiatives.

(\$ in millions)	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
Cash	\$144.7	\$158.3	\$120.2	\$118.4	\$86.3	\$58.0
Debt	\$739.6	\$792.2	\$792.4	\$849.4	\$860.2	\$863.4
Accounts Receivable, Net	\$240.5	\$221.6	\$201.8	\$187.0	\$183.5	\$178.8
Cash Flow from Operations	(\$61.3)	(\$17.8)	(\$24.1)	(\$51.5)	(\$32.6)	(\$17.8)
Cash Flow from Investing	(\$15.1)	(\$17.8)	(\$10.8)	(\$11.8)	(\$8.0)	(\$10.2)
Free Cash Flow ⁽¹⁾	(\$76.4)	(\$35.6)	(\$34.9)	(\$63.3)	(\$40.6)	(\$28.1)

Fifth consecutive quarter of YOY Free Cash Flow improvement

smile

2023 guidance & macro customer impacts.





2023 Guidance includes Strategic Actions to Reduce Costs and Focus on Critical Business Needs.

SDC engaged a third-party advisor to evaluate cost saving opportunities while protecting key investment initiatives. Q1 2023 implementation with transition over a 6-month period.

\$120MM to \$140MM annual run rate cash savings by end of 2023

COST SAVINGS PLAN

G&A Savings: \$50MM to 55MM

• Protects near-term profitability initiatives that launch during 2023

Marketing and Selling Savings: \$60MM to \$65MM

- Continuing efforts to drive marketing efficiency and leverage new initiatives
- Store rationalization and leverage new initiatives

CapEx Savings: \$10MM to \$15MM

- Reduction in overall investment by focusing on key initiatives
- Completion of initiative investments to launch in 2023



2023 Updated Annual Guidance.

Guidance now includes contributions from the 2023 delayed rollout of the SmileMaker Platform and launch of the CarePlus solution which continues to scale with expectations to contribute revenue and Adjusted EBITDA in the back half of the year

Between \$425MM to \$475MM

- Includes contributions from SmileMaker and CarePlus in the back half of 2023
- Macro factors including challenges to consumer spending and sustained high inflation are key drivers for range of aligner orders driving second half revenue

Gross Margin: 73.0% to 76.0%

• Efficiencies gained with increased aligner volumes leveraging fixed costs

Adjusted EBITDA⁽¹⁾: (\$40MM) to (\$10MM)

- Range largely driven by top line revenue results
- Includes investments in additional SmileShops as a key component in returning to growth and driving our SmileMaker and CarePlus initiatives
- Positive Adjusted EBITDA by Q3 2023

Capex: \$30MM to \$35MM

One-Time Costs: \$12MM to \$15MM

• Reorganization costs which may include lease buyouts, asset impairments related to the closure of regional operating centers and SmileShops, and employee-related costs, including severance and retention payments, associated with the organizational changes



⁽¹⁾ Adjusted EBITDA is a non-GAAP financial measure. See appendix for definition of Adjusted EBITDA. Prior period reconciliations are available in 32 historical SEC filings at https://investors.smiledirectclub.com/financial-filings/sec-filings.

REVENUE

Appendix.





Summary of debt facility.

- SDC U.S. SmilePay SPV ("SPV") is a whollyowned special purpose subsidiary of the Company
- The Company entered into a Loan Agreement (the "Loan Agreement") by and among SPV, as borrower, SmileDirectClub,LLC as the seller and servicer, the lenders from time to time party thereto, and HPS Investment Partners, LLC, as administrative agent and collateral agent
- Subject to certain exceptions, the Loan Agreement is secured by first-priority security interests in SPV's assets, which consist of certain receivables, cash, intellectual property and related assets. SPV's obligations under the Loan Agreement are guaranteed on a limited basis by SmileDirectClub, LLC and SDC Financial LLC (collectively, the "Guarantors").
- This facility enables us to access additional liquidity on favorable terms by leveraging our receivables and providing us with greater flexibility to fuel ongoing operations and execute on growth initiatives.

smile

Secured Debt Facility					
Amount	\$255 million				
Security Interest	Certain Receivables, Cash & IP				
Maturity	42 months				
Delayed Draw Availability	18 months				
Interest	L+700bps Cash & 375bps PIK				
Undrawn Commitment Fee	275bps				

Other SEC related disclosures.





US/Canada vs. ROW.

		US & Canada			ROW	
Q2 2023 Comparison	Q2 2023	% of Total	ြ စ်	Q2 2023	% of Total	QoQ
Total Unique Aligner Orders Shipped	36,909	78.9%	(23.3%)	9,865	21.1%	(14.4%)
Average Aligner Gross Sales Price	\$1,979	N/A	0.6%	\$1,962	N/A	4.4%
Total Revenue	\$84.0mm	82.5%	(15.4%)	\$17.8mm	17.5%	(13.1%)
Gross Profit	\$61.0mm	83.7%	(16.4%)	\$11.9mm	16.3%	(14.2%)
Gross Margin %	72.6%			66.8%		
S&M	\$38.4mm	77.3%		\$11.3mm	22.7%	
As % of Total Revenue	45.7%			63.3%		
G&A	\$47.7mm	80.1%		\$11.8mm	19.9%	
As % of Total Revenue	56.8%			66.5%		
Adj EBITDA ⁽¹⁾	(\$5.8mm)			(\$7.8mm)		



Net Income to Adjusted EBITDA.

	Three Months	Ended June 30,
(In thousands)	2023	2022
Net loss	(\$53,796)	(\$65,486)
Depreciation and amortization	15,518	19,580
Total interest expense	8,527	4,454
Income tax (benefit) expense	492	256
Lease abandonment and impairment of long-lived assets	4,811	-
Restructuring and other related costs	3,709	3,168
Equity-based compensation	5,345	8,560
Other non-operating general and administrative costs	1,813	6,306
Adjusted EBITDA	(\$13,581)	(\$23,162)

smile

SmileShop Bridge.

Currently 7% of SmileShops are located within Dental Practices

Market	Mar 31, 2021	Jun 30, 2021	Sept 30, 2022	Dec 31, 2022	Mar 31, 2023	Jun 30, 2023
United States	85	88	89	93	81	99
Canada	8	8	7	7	7	7
United Kingdom	7	9	9	12	13	15
Australia	7	7	6	6	5	5
France	2	5	5	5	0	0
Ireland	1	1	1	1	2	2
Total	110	118	117	124	108	128



Cash Flow from Operations to Free Cash Flow.

	Three Months Ended June 30,					
(In thousands)	2023	2022				
Cash Flow From Operations	(\$17,838)	(\$17,840)				
Cash Flow From Investing	(10,244)	(17,754)				
Free Cash Flow	(\$28,082)	(\$35,594)				

Gross to Net Revenue Bridge.

(\$ in minions, except for Angliers Shipped un	u ASI J											
	C	3 2021	(Q4 2021	Q1 2022	Q2 2022	Q3 2022	(Q4 2022	Q1 2023	0	Q2 2023
Total Unique Aligner Orders Shipped ⁽¹⁾		69,906		66,133	76,254	62,705	52,367		41,462	59,645		46,774
Average Aligner Gross Sales Price ("ASP")		\$1,900		\$1,899	\$1,890	\$1,917	\$1,902		\$1,960	\$1,949		\$1,976
Aligner Gross Revenue	\$	132.8	\$	125.6	\$ 144.2	\$ 120.2	\$ 99.6	\$	81.3	116.3	\$	92.4
Implicit Price Concession ⁽²⁾		(10.7)		(13.6)	(13.9)	(11.0)	(8.9)		(10.4)	(11.4)		(8.1)
Reserves and other adjustments ⁽³⁾		(13.9)		(13.0)	(11.3)	(10.3)	(10.6)		(8.1)	(10.5)		(8.3)
Aligner Revenue ⁽⁴⁾	\$	108.3	\$	99.0	\$ 118.9	\$ 98.9	\$ 80.1	\$	62.8	94.4	\$	76.0
Financing Revenue ⁽⁵⁾		10.9		9.8	9.1	9.0	8.2		7.4	6.9		7.1
Other Revenue and adjustments ⁽⁶⁾		18.5		17.5	23.5	17.8	18.4		16.4	18.4		18.7
Total Net Revenue	\$	137.7	\$	126.3	\$ 151.6	\$ 125.7	\$ 5 106.8	\$	86.5	119.8	\$	101.8

(\$ in millions; except for Aligners Shipped and ASP)

Note: All information in this file is publicly available from our SEC filings.

- (1) Each unique aligner order shipped represents a single contracted member.
- (2) Estimated based on historical write-off percentages and expected net collections. Excludes implicit price concessions on financing revenue.
- (3) Includes impression kit revenue, refunds and sales tax.
- (4) As defined in quarterly and annual filings (Aligner Gross Revenue less IPC and Reserves and other adjustments).
- (5) Represents interest income earned on our SmilePay financing program, net of IPC starting in 2019, as noted in footnote 2 above.
- (6) Includes net revenue related to retainers, whitening, and other ancillary products.



Summary of convertible debt terms.

 This convertible debt financing strengthens our balance sheet, with minimal equity dilution, and fortifies us against a protracted COVID environment, while also enabling to us to comfortably execute our growth strategy over the coming years, while also investing in R&D, innovation, and other business development opportunities.

Convertib	Convertible Debt Key Terms					
Base Deal Size	\$650 million					
Green Shoe (exercised)	\$97.5 million					
Coupon	0.00%					
Conversion Premium/Price	40.0% / \$18.06					
Settlement Date	February 9, 2021					
Maturity	February 1, 2026					
Capped Call Key Terms						
Capped Call Lower Strike	40.0% / \$18.06					
Capped Call Upper Strike	100.0% / \$25.80					
Net Premium	9.3% of proceeds					
Effective all-in Rate/Terms	~2.0% Cost of Capital up 100%					



